To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
18 Current news about the topic performance materialsrss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
RMB 100 million fund targets startups close to the three business sectors of Merck as well as new businesses
Merck announced an RMB 100 million (€ 13 million) seed fund targeted at startups in China. The company also officially opened its innovation hub in Shanghai and announced plans to officially open a second innovation hub in Guangzhou in November. “Our RMB 100 million China seed fund underlines our ...
Startups can apply for programs at Merck headquarters in Darmstadt or in China
Merck announced that it has opened the next round of applications for startup companies to participate in the global Merck Accelerator program. Startups can choose to participate in one of the two programs, either at the company’s Innovation Center at global headquarters in Darmstadt or at its ...
Company signed agreement with Guangzhou Development District
Merck signed an agreement with the Guangzhou Development District on innovation development in Southern China. Pursuant to this agreement, Merck will establish an innovation hub in Guangzhou scheduled to open September 2019. “China is a major innovation hotspot and one of our most important ...
Performance Materials realigns R&D
Merck expects strong growth impetus starting next year, as the company reported to analysts and investors at its Capital Markets Day. “2018 has been a challenging year for Merck. We have made future-oriented decisions that will lead to profitable growth as of next year,” said Stefan Oschmann, ...
Funding of up to € 350,000 per research grant or up to € 30,000 per research challenge
Merck announced several research grants and challenges during the company’s 350th anniversary year in addition to already existing initiatives. The new research grants and challenges are mainly directed to scientists working in institutes, universities or start-up companies around the world. “The ...
Merck held its 23rd Annual General Meeting. The company’s 350th anniversary was one of the overriding themes. Stefan Oschmann, CEO and Chairman of the Executive Board, reported to around 1,300 Merck shareholders on business developments and strategic moves in 2017 and presented an outlook for the ...
Organic sales growth in all regions
Merck met its targets for 2017 and achieved important strategic successes with the approvals of two new medicines. Sales increased over the previous year whereas EBITDA pre, which was adversely impacted by negative foreign exchange effects, declined slightly. “2017 was a good year for Merck. We ...
Merck reported third-quarter Group sales at the year-earlier level. EBITDA pre exceptionals decreased by -8.3% owing to higher spending on research and development, preparations for the market launches in Healthcare, as well as the business performance of Liquid Crystals. “We generated healthy ...
Merck informed analysts and investors at its 2017 Capital Markets Day about the progress being made and the challenges faced by the Group and its three business sectors. In addition, CEO Stefan Oschmann and CFO Marcus Kuhnert provided a strategic outlook of the key growth drivers for the years ...
Life Science and Healthcare drive organic growth
Merck reported an increase in sales in the second quarter of 2017 along with a decline in EBITDA pre exceptionals compared with the year-earlier period. Merck confirmed its earnings guidance following the first six months of 2017. “We have set the course for future growth. By focusing on ...